🔎 Trials Near Me

Domov › Ateroskleróza › Texas

Klinické štúdie Ateroskleróza v štáte Texas

11 štúdií pre Ateroskleróza hľadá účastníkov v zariadeniach v štáte Texas.

Mestá v štáte Texas

Oficiálny text štúdie (anglicky)

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  • Horizon Clinical Research Group, Cypress
  • Cardiovascular Specialists of Willowbrook, Houston
  • Texas Cardiology Associates of Houston, Kingwood
  • a 2 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07783802

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

  • Southwest Family Medicine Associates, Dallas
  • East Texas Cardiology PA, Houston
  • Cardiovascular Specialists of Willowbrook, Houston
  • a 1 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07448038

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

  • PharmaTex Research, Amarillo
  • St. David's Heart & Vascular PLLC dba Austin Heart, Austin
  • Velocity Clinical Research, Austin, Austin
  • a 18 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT07157774

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • PharmaTex Research, LLC, Amarillo
  • Austin Heart, Austin
  • Velocity Clinical Research - Austin, Austin
  • a 22 ďalších
Prebieha náborFáza 3
Vek 45 až 99 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07037433

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  • PharmaTex Research, LLC, Amarillo
  • Pulse Care Heart and Vascular, Carrollton
  • DM Clinical Research - Dallas, Tomball
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07521007

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  • Cussimanio Research Group LLC, Austin
  • Research Management, Inc., Austin
  • MW Clinical Research Center, Beaumont
  • a 22 ďalších
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT05485961

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

  • Research Site, Amarillo
  • Research Site, Beaumont
  • Research Site, Brownsville
  • a 33 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT07000357

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

  • PharmaTex Research LLC, Amarillo
  • Kelsey Seybold Research Foundation, Houston
  • Northwest Houston Clinical Research PLLC, Tomball
Prebieha náborFáza 3
Vek 18 až 80 · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT06813911

Pelacarsen Roll-over Extension Program

  • Plano Primary Care Clinic, Allen
  • Pharma Tex Research, Amarillo
  • SW Family Medicine Associates, Dallas
  • a 8 ďalších
Prebieha náborFáza 3
Vek 18 až 100 · Všetky pohlavia · Aktualizované 29. 7. 2026 · NCT06875973

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Prebieha náborFáza 4
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 12. 2025 · NCT02915198

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

  • UT Health Houston, Houston
Prebieha náborFáza 2
Vek 40 a viac · Všetky pohlavia · Aktualizované 17. 12. 2025 · NCT05488431

Z ClinicalTrials.gov, dáta načítané 4. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.